In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on AIM ImmunoTech (AIM – Research Report), with a price target of $3.00. The company’s shares opened today at $0.78.
According to TipRanks, McCarthy is an analyst with an average return of -36.4% and a 19.32% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Atossa Therapeutics, Capricor Therapeutics, and VistaGen Therapeutics.
Currently, the analyst consensus on AIM ImmunoTech is a Moderate Buy with an average price target of $3.00.
See the top stocks recommended by analysts >>
Based on AIM ImmunoTech’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $33 thousand and a GAAP net loss of $3.82 million. In comparison, last year the company earned a revenue of $28 thousand and had a GAAP net loss of $3.58 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AIM ImmunoTech, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Orlando, FL.
Read More on AIM:
- Nokia Corporation: Repurchase of own shares on 16.08.2022
- Ginkgo Bioworks Stock Jumps after Q2 Revenue Explodes
- Ladenburg Thalmann & Co. Reaffirms Their Buy Rating on Palatin Technologies (PTN)
- Analysts Offer Insights on Healthcare Companies: SCYNEXIS (SCYX) and Clene (CLNN)
- Security National Life Insurance Company joins Live Oak Bank’s funeral business lending program
